Sanofi pledges €10m to Notre Dame, but faces backlashSanofi has said that it will donate 10 million Euros to the rebuilding of Notre Dame cathedral in Share XSanofi pledges €10m to Notre Dame, but faces backlashhttps://pharmaphorum.com/news/sanofi-pledges-e10m-to-notre-dame-but-faces-backlash/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Sanofi and Alnylam conclude research phase of RNAi allianceSanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance Share XSanofi and Alnylam conclude research phase of RNAi alliancehttps://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/
Sanofi may airlift medicines into UK after BrexitFrance’s Sanofi has said it may fly supplies of flu vaccine into the UK if Brexit causes travel Share XSanofi may airlift medicines into UK after Brexithttps://pharmaphorum.com/news/sanofi-may-airlift-medicines-into-uk-after-brexit/
FDA unconvinced by Sanofi’s Zynquista in type 1 diabetesSanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share XFDA unconvinced by Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
Eyeforpharma Barcelona 2019 roundupThis year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting Share XEyeforpharma Barcelona 2019 rounduphttps://pharmaphorum.com/digital/eyeforpharma-barcelona-2019-roundup/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
CHMP okays Sanofi’s Zynquista in type 1 diabetesSanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a Share XCHMP okays Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/chmp-okays-sanofis-zynquista-in-type-1-diabetes/
Sanofi/Regeneron’s Dupixent shows more promise in nasal polypsSanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase Share XSanofi/Regeneron’s Dupixent shows more promise in nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-shows-more-promise-in-nasal-polyps/
